The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial

INTRODUCTION: The clinical utility of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) has yet to be established. This study aimed to compare the effects of denosumab on bone mineral density (BMD) and bone turnover markers to those of alendronate in patients with GIOP. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Iseri, Ken, Iyoda, Masayuki, Watanabe, Makoto, Matsumoto, Kei, Sanada, Daisuke, Inoue, Takashi, Tachibana, Shohei, Shibata, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854344/
https://www.ncbi.nlm.nih.gov/pubmed/29543887
http://dx.doi.org/10.1371/journal.pone.0193846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854344/
https://www.ncbi.nlm.nih.gov/pubmed/29543887
http://dx.doi.org/10.1371/journal.pone.0193846

Ejemplares similares